These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26436548)

  • 21. Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.
    Dubovsky SL
    Expert Opin Drug Metab Toxicol; 2014 May; 10(5):759-66. PubMed ID: 24684240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of NMDA receptors in the pathophysiology and treatment of mood disorders.
    Ghasemi M; Phillips C; Trillo L; De Miguel Z; Das D; Salehi A
    Neurosci Biobehav Rev; 2014 Nov; 47():336-58. PubMed ID: 25218759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroactive steroid levels in patients with generalized anxiety disorder.
    Semeniuk T; Jhangri GS; Le Mellédo JM
    J Neuropsychiatry Clin Neurosci; 2001; 13(3):396-8. PubMed ID: 11514647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anxiety and major depression comorbidity in a family study of obsessive-compulsive disorder.
    Carter AS; Pollock RA; Suvak MK; Pauls DL
    Depress Anxiety; 2004; 20(4):165-74. PubMed ID: 15643633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.
    MacKenzie EM; Odontiadis J; Le Mellédo JM; Prior TI; Baker GB
    Cell Mol Neurobiol; 2007 Aug; 27(5):541-74. PubMed ID: 17235696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The complex roles of neurosteroids in depression and anxiety disorders.
    Longone P; Rupprecht R; Manieri GA; Bernardi G; Romeo E; Pasini A
    Neurochem Int; 2008; 52(4-5):596-601. PubMed ID: 17996986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Web-based screening instrument for depression and anxiety disorders in primary care.
    Farvolden P; McBride C; Bagby RM; Ravitz P
    J Med Internet Res; 2003; 5(3):e23. PubMed ID: 14517114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationships among pain, anxiety, and depression in primary care.
    Means-Christensen AJ; Roy-Byrne PP; Sherbourne CD; Craske MG; Stein MB
    Depress Anxiety; 2008; 25(7):593-600. PubMed ID: 17932958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroactive steroids in schizophrenia.
    Shulman Y; Tibbo PG
    Can J Psychiatry; 2005 Oct; 50(11):695-702. PubMed ID: 16363462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment.
    Ströhle A; Romeo E; di Michele F; Pasini A; Yassouridis A; Holsboer F; Rupprecht R
    Am J Psychiatry; 2002 Jan; 159(1):145-7. PubMed ID: 11772707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.
    Zwanzger P; Rupprecht R
    J Psychiatry Neurosci; 2005 May; 30(3):167-75. PubMed ID: 15944741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Focus on GABA(A) receptor function. A comparative analysis of in vivo imaging studies in neuropsychiatric disorders.
    Nikolaus S; Hautzel H; Müller HW
    Nuklearmedizin; 2014; 53(6):227-37. PubMed ID: 25483111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steroids, neuroactive steroids and neurosteroids in psychopathology.
    Dubrovsky BO
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):169-92. PubMed ID: 15694225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased neuroactive steroid concentrations in women with bipolar disorder or major depressive disorder.
    Hardoy MC; Serra M; Carta MG; Contu P; Pisu MG; Biggio G
    J Clin Psychopharmacol; 2006 Aug; 26(4):379-84. PubMed ID: 16855455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Major depression, generalized anxiety disorder, and panic disorder in patients scheduled for knee arthroplasty.
    Riddle DL; Wade JB; Jiranek WA
    J Arthroplasty; 2010 Jun; 25(4):581-8. PubMed ID: 19493643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Finasteride treatment and neuroactive steroid formation.
    Dusková M; Hill M; Hanus M; Matousková M; Stárka L
    Prague Med Rep; 2009; 110(3):222-30. PubMed ID: 19655698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in neuroactive steroid secretion associated with CO2-induced panic attacks in normal individuals.
    Brambilla F; Perini G; Serra M; Pisu MG; Zanone S; Toffanin T; Milleri S; Garcia CS; Biggio G
    Psychoneuroendocrinology; 2013 Oct; 38(10):2234-42. PubMed ID: 23702252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders.
    Belzung C; Yalcin I; Griebel G; Surget A; Leman S
    CNS Neurol Disord Drug Targets; 2006 Apr; 5(2):135-45. PubMed ID: 16611088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neonatal exposure to estradiol in rats influences neuroactive steroid concentrations, GABAA receptor expression, and behavioral sensitivity to anxiolytic drugs.
    Calza A; Sogliano C; Santoru F; Marra C; Angioni MM; Mostallino MC; Biggio G; Concas A
    J Neurochem; 2010 Jun; 113(5):1285-95. PubMed ID: 20345753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.